logo

For the Inventor, By the Inventor

Bedminster, NJ, United States of America

Aerie Pharmaceuticals, Inc.

USPTO Granted Patents = 60

% Expired Patents = 1.7



Trademarks = 2

Forward Citations = 970

Loading Chart...
Loading Chart...

46 inventors (with patents filed for the assignee):

goldMedal Mitchell Anthony deLong (54 out of 71 patents)

silverMedal Jill Marie Sturdivant (52 out of 57 patents)

bronzeMedal Susan Marie Royalty (30 out of 31 patents)

4.  Casey Kopczynski (14 out of 19 patents)

5.  Cheng-Wen Lin (12 out of 15 patents)

6.  Geoffrey Richard Heintzelman (12 out of 12 patents)

7.  Cynthia L Lichorowic (8 out of 9 patents)

8.  Andriy Kornilov (5 out of 18 patents)

9.  Ramesh Krishnamoorthy (3 out of 7 patents)

10.  Eric Carlson (3 out of 3 patents)

11.  Tomas Navratil (3 out of 11 patents)

12.  Gilles Chambournier (3 out of 11 patents)

13.  Michael Robert Turner (2 out of 42 patents)

14.  Weimin Liu (2 out of 46 patents)

15.  Stuart Williams (2 out of 2 patents)


Core Competencies:
Ocular Conditions
Glaucoma Treatments
Intravitreal Delivery
Dual Mechanism Inhibitors
Amino-Isoquinoline Compounds
Combination Therapy
Steroid Conjugates
Rho Kinase Inhibitors
Aryl Cyclopropyl-Amino Compounds
Beta-Amino Compounds
6-Aminoisoquinoline
Isoquinoline Compounds

60 patents:

1. 12018012 - Aryl cyclopropyl-amino-isoquinolinyl amide compounds (2024-06-25),
2. 11891376 - Aryl cyclopropyl-amino-isoquinolinyl amide compounds (2024-02-06),
3. 11850221 - Ophthalmic pharmaceutical compositions and uses thereof (2023-12-26),
4. 11707460 - Ophthalmic compositions (2023-07-25),
5. 11691950 - Isoquinoline-steroid conjugates and uses thereof (2023-07-04),
6. 11618748 - Dual mechanism inhibitors for the treatment of disease (2023-04-04),
7. 11590123 - Ophthalmic compositions (2023-02-28),
8. 11427563 - Aryl cyclopropyl-amino-isoquinolinyl amide compounds (2022-08-30),
9. 11389441 - Ophthalmic compositions (2022-07-19),
10. 11312700 - Aryl cyclopropyl-amino-isoquinolinyl amide compounds (2022-04-26),
11. 11197853 - Combination therapy (2021-12-14),
12. 11185538 - Compositions for treating glaucoma or reducing intraocular pressure (2021-11-30),
13. 11117869 - Compounds, compositions and methods for treatment of myopia (2021-09-14),
14. 11116776 - Intravitreal drug delivery systems for the treatment of ocular conditions (2021-09-14),
15. 11059789 - Isoquinoline-steroid conjugates and uses thereof (2021-07-13),
Company Overview
Aerie Pharmaceuticals, Inc. is a biotechnology company based in Bedminster, NJ, specializing in the development of innovative ophthalmic pharmaceuticals. The company focuses on addressing ocular conditions, particularly glaucoma, through advanced therapeutic solutions. Aerie's research encompasses dual mechanism inhibitors, intravitreal delivery systems, and combination therapies, leveraging unique compounds such as amino-isoquinolines and steroid conjugates. Their commitment to improving patient outcomes in eye care positions them as a key player in the ophthalmic pharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Aerie Pharmaceuticals, Inc. USPTO Patent Assignee Logo
60 Patents

#2 in Bedminster, NJ

#250 in New Jersey

#5,999 in US

#12,094 in the World

Bedminster, NJ (US)
Bedminster, NJ, United States of America

Aerie Pharmaceuticals, Inc.

Forward Citations = 970

46 inventors:

goldMedal Mitchell Anthony deLong (54 out of 71 patents)

silverMedal Jill Marie Sturdivant (52 out of 57 patents)

bronzeMedal Susan Marie Royalty (30 out of 31 patents)

4.  Casey Kopczynski (14 out of 19 patents)

5.  Cheng-Wen Lin (12 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aerie Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/aerie-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…